Close
Updates on Tofersen Trials for SOD1-MND

Updates on Tofersen Trials for SOD1-MND

Reading Time: 7 minutes Global biotechnology company Biogen has announced plans to make tofersen, a potential treatment for people whose MND is believed to be driven by mutations in the SOD1 gene, available to more people on an early access programme. Biogen have also revealed that they are conducting a new Phase 3 clinical trial of tofersen in those…